China Nuokang Bio-Pharma Plans a Nasdaq IPO

China Nuokang Bio-Pharmaceutical, a company focused on hematological and cardiovascular drugs, will offer 4.5 million ADSs on the Nasdaq exchange at a price between $10 and $12. The mid-point of the range represents a $50 million debut for Nuokang. The company's main product, the blood clotting agent Baquting, commands a 38% share of its market. More details...